Central mechanisms of abnormal sympathoexcitation in chronic heart failure

Cardiology Research and Practice

Volumn 1, Issue 1, 2012, Pages

  Kishi, Takuya ^a   Hirooka, Yoshitaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ATORVASTATIN; CENTRAL ALPHA2 RECEPTOR; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MOXONIDINE; NITRIC OXIDE; RECEPTOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ABLATION THERAPY; ADRENERGIC STIMULATION; AUTONOMIC NEUROPATHY; BRAIN REGION; CHEMORECEPTOR REFLEX; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENCEPHALITIS; EXERCISE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NERVE CONDUCTION; NONHUMAN; OXIDATIVE STRESS; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84866236508     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.1155/2012/847172     Document Type: Review

References (94)

1. Triposkiadis F., Karayannis G., Giamouzis G., Skoularigis J., Louridas G., Butler J., The sympathetic nervous system in heart failure. physiology, pathophysiology, and clinical implications. Journal of the American College of Cardiology 2009 54 19 1747 1762 2-s2.0-70350513886 10.1016/j.jacc.2009.05.015
2. Floras J. S., Sympathetic nervous system activation in human heart failure. clinical implications of an updated model. Journal of the American College of Cardiology 2009 54 5 375 385 2-s2.0-67650531390 10.1016/j.jacc.2009. 03.061
3. Kishi T., Heart failure as an autonomic nervous system dysfunction. Journal of Cardiology 2012 59 117 122 10.1016/j.jjcc.2011.12.006
4. Watson A. M. D., Hood S. G., May C. N., Mechanisms of sympathetic activation in heart failure. Clinical and Experimental Pharmacology and Physiology 2006 33 12 1269 1274 2-s2.0-33845542345 10.1111/j.1440-1681.2006. 04523.x
5. Dzau V. J., Colucci W. S., Hollenberg N. K., Williams G. H., Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981 63 3 645 651 2-s2.0-0019508224
6. Hogg K., McMurray J., Neurohumoral pathways in heart failure with preserved systolic function. Progress in Cardiovascular Diseases 2005 47 6 357 366 2-s2.0-23944432884 10.1016/j.pcad.2005.02.001
7. Grassi G., Seravalle G., Quarti-Trevano F., Dell'Oro R., Arenare F., Spaziani D., Mancia G., Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension 2009 53 2 205 209 2-s2.0-59849089650 10.1161/HYPERTENSIONAHA.108.121467
8. Zucker I. H., Schultz H. D., Patel K. P., Wang W., Gao L., Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. American Journal of Physiology 2009 297 5 H1557 H1566 2-s2.0-70350452219 10.1152/ajpheart.00073.2009
9. Fisher J. P., Young C. N., Fadel P. J., Central sympathetic overactivity: maladies and mechanisms. Autonomic Neuroscience 2009 148 1-2 5 15 2-s2.0-67349117335 10.1016/j.autneu.2009.02.003
10. Zucker I. H., Hackley J. F., Cornish K. G., Hiser B. A., Anderson N. R., Kieval R., Irwin E. D., Serdar D. J., Peuler J. D., Rossing M. A., Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007 50 5 904 910 2-s2.0-35848932513 10.1161/ HYPERTENSIONAHA.107.095216
11. Houser S. R., Margulies K. B., Murphy A. M., Animal models of heart failure: a scientific statement from the American Heart Association. Circulation Research 2012 111 1 131 150
12. Guyenet P. G., The sympathetic control of blood pressure. Nature Reviews Neuroscience 2006 7 5 335 346 2-s2.0-33745712914 10.1038/nrn1902
13. Wang H., Huang B. S., Ganten D., Leenen F. H. H., Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circulation Research 2004 94 6 843 849 2-s2.0-1842455238 10.1161/01.RES.0000120864.21172.5A
14. Hu L., Zhu D. N., Yu Z., Wang J. Q., Sun Z. J., Yao T., Expression of angiotensin II type 1 (AT1) receptor in the rostral ventrolateral medulla in rats. Journal of Applied Physiology 2002 92 5 2153 2161 2-s2.0-0036081935
15. Huang B. S., Leenen F. H. H., The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction. Current Heart Failure Reports 2009 6 2 81 88 2-s2.0-66749173446 10.1007/s11897-009-0013-9
16. Leenen F. H. H., Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circulation Research 2007 101 3 221 223 2-s2.0-34548300070 10.1161/CIRCRESAHA.107.158261
17. Dupont A. G., Brouwers S., Brain angiotensin peptides regulate sympathetic tone and blood pressure. Journal of Hypertension 2010 28 8 1599 1610 2-s2.0-77954956655 10.1097/HJH.0b013e32833af3b2
18. Reja V., Goodchild A. K., Phillips J. K., Pilowsky P. M., Upregulation of angiotensin AT1 receptor and intracellular kinase gene expression in hypertensive rats. Clinical and Experimental Pharmacology and Physiology 2006 33 8 690 695 2-s2.0-33745945692 10.1111/j.1440-1681.2006.04420.x
19. Allen A. M., Moeller I., Jenkins T. A., Zhuo J., Aldred G. P., Chai S. Y., Mendelsohn F. A. O., Angiotensin receptors in the nervous system. Brain Research Bulletin 1998 47 1 17 28 2-s2.0-0032168399 10.1016/S0361-9230(98)00039- 2
20. Huang B. S., Zheng H., Tan J., Regulation of hypothalamic renin-angiotensin system and oxidative stress by aldosterone. Experimental Physiology 2011 96 1028 1038 10.1113/expphysiol.2011.059840
21. Gao L., Wang W., Li Y. L., Schultz H. D., Liu D., Cornish K. G., Zucker I. H., Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. American Journal of Physiology 2005 288 5 H2271 H2279 2-s2.0-18044375210 10.1152/ajpheart.00949.2004
22. Liu D., Gao L., Roy S. K., Cornish K. G., Zucker I. H., Neuronal angiotensin II type 1 receptor upregulation in heart failure: activation of activator protein 1 and Jun N-terminal kinase. Circulation Research 2006 99 9 1004 1011 2-s2.0-33750447670 10.1161/01.RES.0000247066.19878.93
23. Li Y. F., Wang W., Mayhan W. G., Patel K. P., Angiotensin-mediated increase in renal sympathetic nerve discharge within the PVN: role of nitric oxide. American Journal of Physiology 2006 290 4 R1035 R1043 2-s2.0-33646487461 10.1152/ajpregu.00338.2004
24. Nozoe M., Hirooka Y., Koga Y., Sagara Y., Kishi T., Engelhardt J. F., Sunagawa K., Inhibition of Rac1-derived reactive oxygen species in nucleus tractus solitarius decreases blood pressure and heart rate in stroke-prone spontaneously hypertensive rats. Hypertension 2007 50 1 62 68 2-s2.0-34250828562 10.1161/HYPERTENSIONAHA.107.087981
25. Zimmerman M. C., Zucker I. H., Mitochondrial dysfunction and mitochondrial-produced reactive oxygen species new targets for neurogenic hypertension? Hypertension 2009 53 2 112 114 2-s2.0-59849084399 10.1161/HYPERTENSIONAHA.108.125567
26. Dampney R. A. L., Functional organization of central pathways regulating the cardiovascular system. Physiological Reviews 1994 74 2 323 364 2-s2.0-0028258843
27. Kishi T., Hirooka Y., Kimura Y., Ito K., Shimokawa H., Takeshita A., Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 2004 109 19 2357 2362 2-s2.0-2442706556 10.1161/01.CIR. 0000128695.49900.12
28. Ramchandra R., Hood S. G., Watson A. M. D., Central angiotensin type 1receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure. Hypertension 2012 59 634 641
29. Gao L., Wang W., Liu D., Zucker I. H., Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic heart failure. Circulation 2007 115 24 3095 3102 2-s2.0-34250772396 10.1161/CIRCULATIONAHA.106.677989
30. Gao L., Wang W. Z., Wang W., Zucker I. H., Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla potential mechanism for sympathetic overactivity in heart failure. Hypertension 2008 52 4 708 714 2-s2.0-54749089704 10.1161/HYPERTENSIONAHA.108. 116228
31. Felder R. B., Yu Y., Zhang Z. H., Wei S. G., Pharmacological treatment for heart failure: a view from the brain. Clinical Pharmacology and Therapeutics 2009 86 2 216 220 2-s2.0-67651165004 10.1038/clpt.2009.117
32. Felder R. B., Francis J., Zhang Z. H., Wei S. G., Weiss R. M., Johnson A. K., Heart failure and the brain: new perspectives. American Journal of Physiology 2003 284 2 R259 R276 2-s2.0-0037307029
33. Yu Y., Zhang Z. H., Wei S. G., Chu Y., Weiss R. M., Heistad D. D., Felder R. B., Central gene transfer of interleukin-10 reduces hypothalamic inflammation and evidence of heart failure in rats after myocardial infarction. Circulation Research 2007 101 3 304 312 2-s2.0-34548310441 10.1161/CIRCRESAHA. 107.148940
34. Yu Y., Wei S. G., Zhang Z. H., Gomez-Sanchez E., Weiss R. M., Felder R. B., Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 2008 51 3 727 733 2-s2.0-39749093127 10.1161/HYPERTENSIONAHA.107.099796
35. Wei S. G., Yu Y., Zhang Z. H., Weiss R. M., Felder R. B., Angiotensin II-triggered p44/42 mitogen-activated protein kinase mediates sympathetic excitation in heart failure rats. Hypertension 2008 52 2 342 350 2-s2.0-49849104800 10.1161/HYPERTENSIONAHA.108.110445
36. Huang B. S., Ahmad M., Tan J., Leenen F. H. H., Chronic central versus systemic blockade of AT1 receptors and cardiac dysfunction in rats post-myocardial infarction. American Journal of Physiology 2009 297 3 H968 H975 2-s2.0-69249141072 10.1152/ajpheart.00317.2009
37. Kang Y. M., Ma Y., Elks C., Zheng J. P., Yang Z. M., Francis J., Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor- κ B. Cardiovascular Research 2008 79 4 671 678 2-s2.0-52449118000 10.1093/cvr/cvn119
38. Yu Y., Zhang Z. H., Wei S. G., Serrats J., Weiss R. M., Felder R. B., Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension 2010 55 3 652 659 2-s2.0-77149128988 10.1161/HYPERTENSIONAHA.109.142836
39. Hirooka Y., Brain perivascular macrophages and central sympathetic activation after myocardial infarction: heart and brain interaction. Hypertension 2010 55 3 610 611 2-s2.0-77149163815 10.1161/HYPERTENSIONAHA.109. 145128
40. Kishi T., Hirooka Y., Sunagawa K., Autoimplantation of astrocytes into cardiovascular center of brainstem causes sympathoinhibition and decreases the mortality rate in hypertensive rats. Circulation 2010 122 A13856
41. Kishi T., Hirooka Y., Sunagawa K., Autoimplantation of astrocytes into the cardiovascular center of brainstem causes sympathoinhibition and decreases the mortality rate in myocardial infarction-induced heart failure. Circulation 2011 124 A11489
42. Cardinale J. P., Sriramula S., Mariappan N., Angiotensin II-induced hypertension is modulated by nuclear factor-kB in the paraventricular nucleus. Hypertension 2011 59 113 121
43. Shi P., Diez-Freire C., Jun J. Y., Qi Y., Katovich M. J., Li Q., Sriramula S., Francis J., Sumners C., Raizada M. K., Brain microglial cytokines in neurogenic hypertension. Hypertension 2010 56 2 297 303 2-s2.0-77955484386 10.1161/HYPERTENSIONAHA.110.150409
44. Schiltz J. C., Sawchenko P. E., Specificity and generality of the involvement of catecholaminergic afferents in hypothalamic responses to immune insults. Journal of Comparative Neurology 2007 502 3 455 467 2-s2.0-34147106972 10.1002/cne.21329
45. Block M. L., Zecca L., Hong J. S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007 8 1 57 69 2-s2.0-33845768784 10.1038/nrn2038
46. Yu Y., Zhang Z. H., Wei S. G., Peroxisome proliferator-activated receptor-g regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure. Hypertension 2012 59 477 484 10.1161/HYPERTENSIONAHA.111. 182345
47. Kishi T., Hirooka Y., Sakai K., Shigematsu H., Shimokawa H., Takeshita A., Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release. Hypertension 2001 38 4 896 901 2-s2.0-0035726144
48. Hirooka Y., Kishi T., Sakai K., Shimokawa H., Takeshita A., Effect of overproduction of nitric oxide in the brain stem on the cardiovascular response in conscious rats. Journal of Cardiovascular Pharmacology 2003 41 1 S119 S126 2-s2.0-0037216307
49. Hirooka Y., Shigematsu H., Kishi T., Kimura Y., Ueta Y., Takeshita A., Reduced nitric oxide synthase in the brainstem contributes to enhanced sympathetic drive in rats with heart failure. Journal of Cardiovascular Pharmacology 2003 42 1 S111 S115 2-s2.0-0344586178
50. Sakai K., Hirooka Y., Shigematsu H., Kishi T., Ito K., Shimokawa H., Takeshita A., Sunagawa K., Overexpression of eNOS in brain stem reduces enhanced sympathetic drive in mice with myocardial infarction. American Journal of Physiology 2005 289 5 H2159 H2166 2-s2.0-27144517091 10.1152/ajpheart.00408.2005
51. Hirooka Y., Sagara Y., Kishi T., Sunagawa K., Oxidative stress and central cardiovascular regulationpathogenesis of hypertension and therapeutic aspects. Circulation Journal 2010 74 5 827 835 2-s2.0-77951760596 10.1253/circj.CJ-10-0153
52. Ito K., Kimura Y., Hirooka Y., Sagara Y., Sunagawa K., Activation of Rho-kinase in the brainstem enhances sympathetic drive in mice with heart failure. Autonomic Neuroscience 2008 142 1-2 77 81 2-s2.0-53049101852 10.1016/j.autneu.2008.07.010
53. Ito K., Hirooka Y., Sunagawa K., Blockade of mineralocorticoid receptors improves salt-induced left-ventricular systolic dysfunction through attenuation of enhanced sympathetic drive in mice with pressure overload. Journal of Hypertension 2010 28 7 1449 1458 2-s2.0-77954351476 10.1097/HJH.0b013e328338bb37
54. Ito K., Hirooka Y., Sunagawa K., Acquisition of brain na sensitivity contributes to salt-induced sympathoexcitation and cardiac dysfunction in mice with pressure overload. Circulation Research 2009 104 8 1004 1011 2-s2.0-65449178018 10.1161/CIRCRESAHA.108.188995
55. Ogawa K., Hirooka Y., Kishi T., Sunagawa K., Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure. Journal of Cardiovascular Pharmacology 2011 58 5 543 549 2-s2.0-79961124440 10.1097/FJC.0b013e31822e6b40
56. Hunt S. A., Abraham W. T., Chin M. H., ACC/AHA, 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 112 e154 e235
57. MERIT- Investigators H. F., Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). The Lancet 1999 353 2001 2007
58. Dargie H. J., Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet 2001 357 9266 1385 1390 2-s2.0-0035810547 10.1016/S0140-6736(00) 04560-8
59. Packer M., Fowler M. B., Roecker E. B., Coats A. J. S., Katus H. A., Krum H., Mohacsi P., Rouleau J. L., Tendera M., Staiger C., Holcslaw T. L., Amann-Zalan I., DeMets D. L., Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002 106 17 2194 2199 2-s2.0-0037159310 10.1161/01.CIR.0000035653.72855.BF
60. Poole-Wilson P. A., Swedberg K., Cleland J. G. F., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W. J., Torp-Pedersen C., Scherhag A., Skene A., Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet 2003 362 9377 7 13 2-s2.0-3142776467 10.1016/S0140-6736(03)13800-7
61. Willenheimer R., van Veldhuisen D. J., Silke B., Erdmann E., Follath F., Krum H., Ponikowski P., Skene A., Van De Ven L., Verkenne P., Lechat P., Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005 112 16 2426 2435 2-s2.0-26644463786 10.1161/CIRCULATIONAHA.105.582320
62. Cohn J. N., Archibald D. G., Ziesche S., Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. The New England Journal of Medicine 1986 314 24 1547 1552 2-s2.0-0022623381
63. Colucci W. S., Williams G. H., Braunwald E., Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure. Annals of Internal Medicine 1980 93 3 452 453 2-s2.0-0019153881
64. ALLHAT Collaborative Research Group, Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Journal of the American Medical Association 2000 283 15 1967 1975 2-s2.0-0034685403
65. Starke K., Gothert M., Kilbinger H., Modulation of neurotransmitter release by presynaptic autoreceptors. Physiological Reviews 1989 69 3 864 989 2-s2.0-0024347556
66. Giles T. D., Thomas M. G., Quiroz A. C., Acute and short-term effects of clonidine in heart failure. Angiology 1987 38 7 537 548 2-s2.0-0023185907
67. Ernsberger P., Meeley M. P., Reis D. J., An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medulla. Brain Research 1988 441 1-2 309 318 2-s2.0-0023851497
68. Cohn J. N., Pfeffer M. A., Rouleau J., Sharpe N., Swedberg K., Straub M., Wiltse C., Wright T. J., Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). European Journal of Heart Failure 2003 5 5 659 667 2-s2.0-0346730904 10.1016/S1388-9842(03)00163-6
69. Sumners C., Raizada M. K., Angiotensin II stimulates norepinephrine uptake in hypothalamus-brain stem neuronal cultures. American Journal of Physiology 1986 250 2 C236 C244 2-s2.0-0022471196
70. Benedict C. R., Francis G. S., Shelton B., Johnstone D. E., Kubo S. H., Kirlin P., Nicklas J., Liang C. S., Konstam M. A., Greenberg B., Yusuf S., Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. American Journal of Cardiology 1995 75 16 1151 1157 2-s2.0-0029072884 10.1016/S0002-9149(99)80748-6
71. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine 2003 348 14 1309 1321 2-s2.0-0037417252 10.1056/NEJMoa030207
72. McKinley M. J., Albiston A. L., Allen A. M., Mathai M. L., May C. N., McAllen R. M., Oldfield B. J., Mendelsohn F. A. O., Chai S. Y., The brain renin-angiotensin system: location and physiological roles. International Journal of Biochemistry and Cell Biology 2003 35 6 901 918 2-s2.0-0037409427 10.1016/S1357-2725(02)00306-0
73. Tsuchihashi T., Kagiyama S., Matsumura K., Abe I., Fujishima M., Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. Journal of Hypertension 1999 17 7 917 922 2-s2.0-0033024799 10.1097/00004872-199917070-00007
74. Leenen F. H. H., Yuan B., Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 2001 37 3 981 984 2-s2.0-0035101357
75. Lin Y., Matsumura K., Kagiyama S., Fukuhara M., Fujii K., Iida M., Chronic administration of olmesartan attenuates the exaggerated pressor response to glutamate in the rostral ventrolateral medulla of SHR. Brain Research 2005 1058 1-2 161 166 2-s2.0-26244453700 10.1016/j.brainres.2005.07.070
76. Araki S., Hirooka Y., Kishi T., Yasukawa K., Utsumi H., Sunagawa K., Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. Hypertension Research 2009 32 12 1091 1096 2-s2.0-73849116449 10.1038/hr.2009.160
77. Kishi T., Hirooka Y., Sunagawa K., Sympathoinhibition caused by orally administered telmisartan through inhibition of AT(1) receptor in the rostral ventrolateral medulla. Hypertension Research. In press
78. Gao L., Wang W., Li Y. L., Schultz H. D., Liu D., Cornish K. G., Zucker I. H., Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005 112 12 1763 1770 2-s2.0-25444504787 10.1161/CIRCULATIONAHA.105. 552174
79. Pliquett R. U., Cornish K. G., Peuler J. D., Zucker I. H., Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003 107 19 2493 2498 2-s2.0-0037504350 10.1161/01.CIR.0000065606.63163.B9
80. Gao L., Wang W., Zucker I. H., Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. Journal of Pharmacology and Experimental Therapeutics 2008 326 1 278 285 2-s2.0-45749144314 10.1124/jpet.107.136028
81. Kishi T., Hirooka Y., Mukai Y., Shimokawa H., Takeshita A., Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. Journal of Hypertension 2003 21 2 379 386 2-s2.0-0037332063 10.1097/00004872-200302000- 00030
82. Kishi T., Hirooka Y., Shimokawa H., Takeshita A., Sunagawa K., Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. Clinical and Experimental Hypertension 2008 30 1 3 11 2-s2.0-38549092439 10.1080/10641960701813429
83. Kishi T., Hirooka Y., Konno S., Atorvastatin improves the impaired baroreflex control of stroke-prone spontaneously hypertensive rats through the anti-oxidant effect in the RVLM. Clinical and Experimental Hypertension 2009 31 698 704 10.3109/10641960903407066
84. Kishi T., Hirooka Y., Sympathoinhibitory effects of atorvastatin in hypertension. Circulation Journal 2010 74 12 2552 2553 2-s2.0-78649705224 10.1253/circj.CJ-10-1024
85. Negrao C. E., Middlekauff H. R., Adaptations in autonomic function during exercise training in heart failure. Heart Failure Reviews 2008 13 1 51 60 2-s2.0-37249005434 10.1007/s10741-007-9057-7
86. Fraga R., Franco F. G., Roveda F., de Matos L. N. J., Braga A. M. F. W., Rondon M. U. P. B., Rotta D. R., Brum P. C., Barretto A. C. P., Middlekauff H. R., Negrão C. E., Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. European Journal of Heart Failure 2007 9 6-7 630 636 2-s2.0-34248170301 10.1016/j.ejheart.2007.03.003
87. O'Connor C. M., Whellan D. J., Lee K. L., Keteyian S. J., Cooper L. S., Ellis S. J., Leifer E. S., Kraus W. E., Kitzman D. W., Blumenthal J. A., Rendall D. S., Miller N. H., Fleg J. L., Schulman K. A., McKelvie R. S., Zannad F., Piña I. L., Efficacy and safety of exercise training in patients with chronic heart failure HF-ACTION randomized controlled trial. Journal of the American Medical Association 2009 301 14 1439 1450 2-s2.0-64249125022 10.1001/jama.2009.454
88. Adams V., Doring C., Schuler G., Impact of physical exercise on alterations in the skeletal muscle in patients with chronic heart failure. Frontiers in Bioscience 2008 13 1 302 311 2-s2.0-38449117471 10.2741/2680
89. Krum H., Schlaich M., Whitbourn R., Sobotka P. A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W. T., Esler M., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. The Lancet 2009 373 9671 1275 1281 2-s2.0-64049084640 10.1016/S0140-6736(09)60566-3
90. DiBona G. F., Esler M., Translational medicine: the antihypertensive effect of renal denervation. American Journal of Physiology 2010 298 2 R245 R253 2-s2.0-75449083560 10.1152/ajpregu.00647.2009
91. Simplicity HTN-2 Investigators, Renal sympathetic denervation in patients with treatment-resistant hypertension (The Simplicity HTN-2 Trail): a randomized controlled trial. The Lancet 2010 376 1903 1909
92. Calaresu F. R., Ciriello J., Renal afferent nerves affect discharge rate of medullary and hypothalamic single units in the cat. Journal of the Autonomic Nervous System 1981 3 24 311 320 2-s2.0-0019409362
93. Ciriello J., Calaresu F. R., Central projections of afferent renal fibers in the rat: an anterograde transport study of horseradish peroxidase. Journal of the Autonomic Nervous System 1983 8 3 273 285 2-s2.0-0020523326 10.1016/0165-1838(83)90110-8
94. Stella A., Golin R., Genovesi S., Zanchetti A., Renal reflexes in the regulation of blood pressure and sodium excretion. Canadian Journal of Physiology and Pharmacology 1987 65 8 1536 1539 2-s2.0-0023394595